Evox Therapeutics Ltd

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
EVOX Therapeutics, a spin out from University of Oxford, UK and Karolinska Institute, Sweden, was established in 2016, with $13 million in a Series A funding, and has since completed a further $46 million Series B funding round. Evox is progressing its proprietary pipeline into the clinic. The technology is based on harnessing, the natural delivery capabilities of extracellular vesicles engineered for tissue targeted delivery of different cargo’s thereby developing an entirely novel class of biotherapeutics, Exosomes.

Our engineered exosomes can deliver drug cargos with a wide range of drug modalities, from small molecules, proteins, antibodies to nucleic acids. In addition, by engineering of Exosomes to express tissue specific ligands we can target different cell types and organs, much of which has been proven in vivo.
Our pipeline exploits this technology, targeting hard to treat rare diseases.
We are inte
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
EVX 101
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
VP Business Development
Evox Therapeutics Ltd